Cargando…
Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
BACKGROUND: A systematic review was conducted to assess the cost-effectiveness of routine varicella and herpes zoster (HZ) vaccination in high-income countries estimated by modelling studies. METHODS: A PubMed search was performed to identify relevant studies published before October 2013. Studies w...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455277/ https://www.ncbi.nlm.nih.gov/pubmed/26041469 http://dx.doi.org/10.1186/s12889-015-1861-8 |
_version_ | 1782374733993476096 |
---|---|
author | Damm, Oliver Ultsch, Bernhard Horn, Johannes Mikolajczyk, Rafael T. Greiner, Wolfgang Wichmann, Ole |
author_facet | Damm, Oliver Ultsch, Bernhard Horn, Johannes Mikolajczyk, Rafael T. Greiner, Wolfgang Wichmann, Ole |
author_sort | Damm, Oliver |
collection | PubMed |
description | BACKGROUND: A systematic review was conducted to assess the cost-effectiveness of routine varicella and herpes zoster (HZ) vaccination in high-income countries estimated by modelling studies. METHODS: A PubMed search was performed to identify relevant studies published before October 2013. Studies were included in the review if they (i) evaluated the cost-effectiveness of routine childhood or adolescent varicella vaccination and/or HZ vaccination targeting the elderly, and if they (ii) reported results for high-income countries. RESULTS: A total of 38 model-based studies were identified that fulfilled the inclusion criteria. Routine childhood or adolescent varicella vaccination was cost-effective or cost-saving from a payer perspective and always cost-saving from a societal perspective when ignoring its potential impact on HZ incidence due to reduced or absent exogenous boosting. The inclusion of the potential impact of childhood varicella vaccination on HZ led to net quality-adjusted life-year (QALY) losses or incremental cost-effectiveness ratios exceeding commonly accepted thresholds. Additional HZ vaccination could partially mitigate this effect. Studies focusing only on the evaluation of HZ vaccination reported a wide range of results depending on the selected target age-group and the vaccine price, but most found HZ vaccination to be a cost-effective or marginally cost-effective intervention. Cost-effectiveness of HZ vaccination was strongly dependent on the age at vaccination, the price of the vaccine, the assumed duration of protection and the applied cost per QALY threshold. CONCLUSIONS: While HZ vaccination is mostly considered cost-effective, cost-effectiveness of varicella vaccination primarily depends on the in- or exclusion of exogenous boosting in the model. As a consequence, clarification on the role of exogenous boosting is crucial for decision-making regarding varicella vaccination. |
format | Online Article Text |
id | pubmed-4455277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44552772015-06-05 Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries Damm, Oliver Ultsch, Bernhard Horn, Johannes Mikolajczyk, Rafael T. Greiner, Wolfgang Wichmann, Ole BMC Public Health Research Article BACKGROUND: A systematic review was conducted to assess the cost-effectiveness of routine varicella and herpes zoster (HZ) vaccination in high-income countries estimated by modelling studies. METHODS: A PubMed search was performed to identify relevant studies published before October 2013. Studies were included in the review if they (i) evaluated the cost-effectiveness of routine childhood or adolescent varicella vaccination and/or HZ vaccination targeting the elderly, and if they (ii) reported results for high-income countries. RESULTS: A total of 38 model-based studies were identified that fulfilled the inclusion criteria. Routine childhood or adolescent varicella vaccination was cost-effective or cost-saving from a payer perspective and always cost-saving from a societal perspective when ignoring its potential impact on HZ incidence due to reduced or absent exogenous boosting. The inclusion of the potential impact of childhood varicella vaccination on HZ led to net quality-adjusted life-year (QALY) losses or incremental cost-effectiveness ratios exceeding commonly accepted thresholds. Additional HZ vaccination could partially mitigate this effect. Studies focusing only on the evaluation of HZ vaccination reported a wide range of results depending on the selected target age-group and the vaccine price, but most found HZ vaccination to be a cost-effective or marginally cost-effective intervention. Cost-effectiveness of HZ vaccination was strongly dependent on the age at vaccination, the price of the vaccine, the assumed duration of protection and the applied cost per QALY threshold. CONCLUSIONS: While HZ vaccination is mostly considered cost-effective, cost-effectiveness of varicella vaccination primarily depends on the in- or exclusion of exogenous boosting in the model. As a consequence, clarification on the role of exogenous boosting is crucial for decision-making regarding varicella vaccination. BioMed Central 2015-06-05 /pmc/articles/PMC4455277/ /pubmed/26041469 http://dx.doi.org/10.1186/s12889-015-1861-8 Text en © Damm et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Damm, Oliver Ultsch, Bernhard Horn, Johannes Mikolajczyk, Rafael T. Greiner, Wolfgang Wichmann, Ole Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries |
title | Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries |
title_full | Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries |
title_fullStr | Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries |
title_full_unstemmed | Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries |
title_short | Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries |
title_sort | systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455277/ https://www.ncbi.nlm.nih.gov/pubmed/26041469 http://dx.doi.org/10.1186/s12889-015-1861-8 |
work_keys_str_mv | AT dammoliver systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries AT ultschbernhard systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries AT hornjohannes systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries AT mikolajczykrafaelt systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries AT greinerwolfgang systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries AT wichmannole systematicreviewofmodelsassessingtheeconomicvalueofroutinevaricellaandherpeszostervaccinationinhighincomecountries |